Supplementary Table 1. The PD-1 inhibitor of the study patients

|  |  |  |  |
| --- | --- | --- | --- |
| PD-1 inhibitor | Entire group  (n=76) | TACE-IO  (n=45) | SBRT-IO  (n=31) |
| Toripalimab | 55 (72.4) | 32 (71.1) | 23 (74.2) |
| Sintilimab | 21 (27.6) | 13 (28.9) | 8 (25.8) |